Hangzhou, China, Dec. 24, 2025 — WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a China-based medical device supplier, today announced via its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and other subsidiaries in China that it will implement a reverse stock split of its ordinary shares at a 1-for-100 ratio (the “Reverse Stock Split”). The Company’s Class A ordinary shares will commence trading on a post-split basis when markets open on December 29, 2025, and will continue to be listed on the Nasdaq Capital Market under the ticker symbol “WOK,” accompanied by a new CUSIP number: G9767H125.
The Reverse Stock Split has been approved by the Company’s shareholders and board of directors, and is being carried out primarily to maintain compliance with Nasdaq Marketplace Rule 5550(a)(2), which governs the minimum bid price requirement for the Company’s Class A ordinary shares.
Fractional shares resulting from the Reverse Stock Split will be rounded up to the nearest whole number, and no fractional shares will be issued. The split affects all shareholders equally and will not alter any shareholder’s percentage ownership in the Company’s outstanding ordinary shares, except for minor adjustments arising from the rounding of fractional shares.
Upon the Reverse Stock Split’s effectiveness, every 100 issued and outstanding Class A ordinary shares of the Company as of the effective date will automatically merge into one Class A ordinary share, and every 100 issued and outstanding Class B ordinary shares will similarly combine into one Class B ordinary share.
About WORK Medical Technology Group LTD
WORK Medical Technology Group LTD, through its subsidiary Work (Hangzhou) Medical Treatment Equipment Co., Ltd. and other subsidiaries in China, operates as a medical device supplier that develops and manufactures Class I and II medical devices, and sells Class I and II disposable medical devices via its operating subsidiaries in the country. The Company’s diverse product portfolio includes 21 items, such as customized and multifunctional masks and other medical consumables. All products are available in 34 provincial-level administrative regions across China, with 15 of them sold in over 30 countries globally. The Company has earned multiple quality-focused manufacturing certifications and registered 17 products with the U.S. Food and Drug Administration (FDA), enabling those products to enter the U.S. market. For more information, please visit the Company’s website: .
Forward-Looking Statements
This press release includes forward-looking statements, including those made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements can be identified by terms like “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will,” and their variations or similar expressions. Any statements in this release that do not reflect historical facts may be deemed forward-looking statements. These forward-looking statements are based on the Company’s current expectations, estimates, and projections as of the date of this release, and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those stated or implied. While the Company believes the expectations in these statements are reasonable, it cannot guarantee their accuracy. The Company cautions investors that actual outcomes may vary significantly from anticipated results and encourages them to review other factors affecting future results outlined in its annual report on Form 20-F and other filings with the U.S. Securities and Exchange Commission. The Company explicitly disclaims any obligation to update these forward-looking statements unless required by law.
For additional information, please reach out to:
WORK Medical Technology Group LTD
Investor Relations Department
Email:
Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email:
